OncoSec Announces Exclusive License Agreement for Cliniporator® Gene Electrotransfer Platform Developed by IGEA Clinical Biophysics
Retrieved on:
Tuesday, November 24, 2020
PENNINGTON, N.J. and SAN DIEGO, Nov. 24, 2020 /PRNewswire/ --OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company developing intra-tumoral cancer immunotherapies, today announced that it has licensed the exclusive rights to the Cliniporator electroporation or gene electrotransfer platform from IGEA Clinical Biophysics ("IGEA").
Key Points:
- PENNINGTON, N.J. and SAN DIEGO, Nov. 24, 2020 /PRNewswire/ --OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company developing intra-tumoral cancer immunotherapies, today announced that it has licensed the exclusive rights to the Cliniporator electroporation or gene electrotransfer platform from IGEA Clinical Biophysics ("IGEA").
- The license encompasses a broad field of use for gene delivery in oncology, including use as part of OncoSec's visceral lesion applicator (VLA) program.
- IGEA has clinical experience with gene therapy as well, which OncoSec will build on.
- Ruggero Cadossi, M.D., IGEA President, added, "We are proud to collaborate with OncoSec, a company committed to delivering innovative therapies to cancer patients.